Literature DB >> 36268094

A digital method to interpret the C-MYC stain in diffuse large B cell lymphoma.

Jayalakshmi Balakrishna1, Jesse Kulewsky1, Anil Parwani1.   

Abstract

Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is a heterogenous group of aggressive lymphomas. C-MYC expression by immunohistochemical stain (IHC) is shown to be an independent prognostic factor in DLBCL. In the clinical setting, MYC stain is currently evaluated by manual quantification with a minimum positivity cut-off 40%. Manual quantification methods can be subjective and may show intra- and interobserver variability and variability between centers. Thus, stains which require definitive quantification such as MYC needs better standardized and precise methods. Here we present a simple digital algorithm for quantitative evaluation of MYC stain in DLBCL, NOS. For this, slides immunostained for C-MYC were scanned at 40X with a high-resolution, Philips Ultra Fast scanner (Koninklijke Philips N.V. Cambridge, MA). The images were manually assessed and appropriate areas with neoplastic cells were selected. For quantification, positive and negative C-MYC staining nuclei were scored using a modified Visiopharm APP Nuclei Detection, AI (Brightfield) using Visiopharm Image Analysis software (Visiopharm, Hørsholm, Denmark version 2018.09). The percentage positivity resulted by the digital method was concordant with the pathologist's interpretation with statistical significance (rs: 0.85968; p (2-tailed) = 0). Minor disadvantages were observed including failure to detect very weak staining and inability to separate neoplastic and non-neoplastic nuclei when admixed in the same area. If combined with a quick manual evaluation, a digital method like this with precision and reproducibility will be of great use in quantitative evaluation of MYC and other similar stains in clinical setting and will reduce intra- and interobserver variability.
© 2022 The Authors.

Entities:  

Keywords:  C-MYC; Diffuse large B-cell lymphoma; Digital quantification; Image analysis; Immunohistochemistry

Year:  2022        PMID: 36268094      PMCID: PMC9576988          DOI: 10.1016/j.jpi.2022.100100

Source DB:  PubMed          Journal:  J Pathol Inform


  8 in total

1.  Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Authors:  Jacinth Joseph; Junsheng Ma; Fady Hennawy; Mustafa Nooruldeen Abdulrazzaq; Neeraj Saini; Romil D Patel; Chitra M Hosing; Amin M Alousi; Paolo Anderlini; Uday R Popat; Muzaffar H Qazilbash; Elizabeth J Shpall; Samer Srour; Partow Kebriaei; Qaiser Bashir; Loretta J Nastoupil; Jason R Westin; Gabriela Rondon; Richard E Champlin; Borje S Andersson; Yago Nieto; Tariq Muzzafar; Sairah Ahmed
Journal:  Transplant Cell Ther       Date:  2021-02-12

2.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

Authors:  Heike Horn; Marita Ziepert; Claudia Becher; Thomas F E Barth; Heinz-Wolfram Bernd; Alfred C Feller; Wolfram Klapper; Michael Hummel; Harald Stein; Martin-Leo Hansmann; Christopher Schmelter; Peter Möller; Sergio Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Reiner Siebert; Markus Loeffler; Andreas Rosenwald; German Ott
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

3.  Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.

Authors:  Hiromichi Takahashi; Katsuhiro Miura; Masaru Nakagawa; Masahiko Sugitani; Yusuke Amano; Daisuke Kurita; Masashi Sakagami; Shimon Ohtake; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Sumiko Kobayashi; Atsuko Hojo; Yujin Kobayashi; Yukio Hirabayashi; Machiko Kusuda; Yoshihiro Hatta; Tomohiro Nakayama; Masami Takei
Journal:  Leuk Lymphoma       Date:  2016-04-13

4.  A simple digital image analysis system for automated Ki67 assessment in primary breast cancer.

Authors:  Anastasia Alataki; Lila Zabaglo; Holly Tovey; Andrew Dodson; Mitch Dowsett
Journal:  Histopathology       Date:  2021-05-05       Impact factor: 5.087

5.  Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.

Authors:  Sriram Balasubramanian; Songbai Wang; Christopher Major; Brendan Hodkinson; Michael Schaffer; Laurie H Sehn; Peter Johnson; Pier Luigi Zinzani; Jodi Carey; S Martin Shreeve; Steven Sun; John Gerecitano; Jessica Vermeulen; Louis M Staudt; Wyndham Wilson
Journal:  Br J Haematol       Date:  2021-05-03       Impact factor: 6.998

6.  Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues.

Authors:  Wan-Hui Yan; Xiang-Nan Jiang; Wei-Ge Wang; Yi-Feng Sun; Yi-Xin Wo; Zheng-Zhi Luo; Qing-Hua Xu; Xiao-Yan Zhou; Jun-Ning Cao; Xiao-Nan Hong; Xiao-Qiu Li
Journal:  Front Oncol       Date:  2020-06-05       Impact factor: 6.244

7.  New MYC IHC Classifier Integrating Quantitative Architecture Parameters to Predict MYC Gene Translocation in Diffuse Large B-Cell Lymphoma.

Authors:  Gilbert Bigras; Wei-Feng Dong; Sarah Canil; Raymond Lai; Didier Morel; Paul E Swanson; Iyare Izevbaye
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-01

8.  Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.

Authors:  Sabina Sangaletti; Fabio Iannelli; Federica Zanardi; Valeria Cancila; Paola Portararo; Laura Botti; Davide Vacca; Claudia Chiodoni; Arianna Di Napoli; Cesare Valenti; Celeste Rizzello; Maria Carmela Vegliante; Federica Pisati; Alessandro Gulino; Maurilio Ponzoni; Mario Paolo Colombo; Claudio Tripodo
Journal:  EBioMedicine       Date:  2020-10-20       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.